First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan

BACKGROUND/AIM: mutation subtypes on treatment response. PATIENTS AND METHODS: mutations who received afatinib 30 mg or 40 mg daily at two university affiliated hospitals. Mutations were categorized as single uncommon, compound (rare + common), or double rare (rare + rare). Clinical characteristics, treatment response, and survival outcomes were compared between mutation subgroups and dosing cohorts. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier analysis and compared with the log-rank test. RESULTS: =0.0287), whereas survival differences by mutation subtype were not significant in the 40 mg cohort. Treatment was well tolerated, with fewer grade ≥3 adverse events in the 30 mg group. CONCLUSION: -mutant NSCLC.